Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 2019’, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH)

– The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects

– The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AD Pharmaceuticals Co Ltd

Amryt Pharma Plc

Beijing Mabworks Biotech Co Ltd

Daewoong Co Ltd

Gemphire Therapeutics Inc

Innovent Biologics Inc

LIB Therapeutics LLC

Lipigon Pharmaceuticals AB

LipimetiX Development Inc

Madrigal Pharmaceuticals Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Homozygous Familial Hypercholesterolemia (HoFH) - Overview 5

Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development 6

Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment 10

Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development 18

Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles 24

Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects 82

Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products 83

Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones 84

Appendix 96

List of Tables

“List of Tables

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by AD Pharmaceuticals Co Ltd, H2 2019

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by Amryt Pharma Plc, H2 2019

Homozygous Familial Hypercholesterolemia (HoFH) – Dormant Projects, H2 2019

Homozygous Familial Hypercholesterolemia (HoFH) – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports